The following secondary endpoints were significantly lower in the CoQ@ group compared with the placebo group : cardiovascular mortality ( @ % vs. @ % , p = @ ) , all-cause mortality ( @ % vs. @ % , p = @ ) , and incidence of hospital stays for HF ( p = @ ) .